Faeth Therapeutics, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Faeth Therapeutics, Inc. (FTH) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $4.48 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-04
- Faeth Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $4.48M, a 1598.11% increase year-over-year.
- Faeth Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $12.90M, a 2697.83% increase year-over-year.
- Faeth Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $254.00K, a 65.35% decline year-over-year.
- Faeth Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $264.00K, a 66.79% decline year-over-year.
- Faeth Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $1.27M, a 59.36% decline from fiscal 2024.
- Faeth Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $3.13M, a 29.61% decline from fiscal 2023.
- Faeth Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $4.45M, a 22.93% decline from fiscal 2022.
- Faeth Therapeutics, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $5.78M, a 2.16% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.48M 10-Q · filed 2026-08-04 | $17.38M derived: sum of 2 quarters · filed 2026-08-04 | ||
| 2026-03-31 | $12.90M 10-Q · filed 2026-08-04 | |||
| 2025-12-31 | $1.27M 10-K · filed 2026-03-30 | |||
| 2025-09-30 | $254.00K 10-Q · filed 2025-11-14 | $518.00K derived: sum of 2 quarters · filed 2026-08-04 | $979.00K derived: sum of 3 quarters · filed 2026-08-04 | |
| 2025-06-30 | $264.00K 10-Q · filed 2026-08-04 | $725.00K derived: sum of 2 quarters · filed 2026-08-04 | ||
| 2025-03-31 | $461.00K 10-Q · filed 2026-08-04 | |||
| 2024-12-31 | $3.13M 10-K · filed 2026-03-30 | |||
| 2024-09-30 | $733.00K 10-Q · filed 2025-11-14 | $1.53M derived: sum of 2 quarters · filed 2025-11-14 | $2.74M derived: sum of 3 quarters · filed 2025-11-14 | |
| 2024-06-30 | $795.00K 10-Q · filed 2025-11-14 | $2.01M derived: sum of 2 quarters · filed 2025-11-14 | ||
| 2024-03-31 | $1.22M 10-Q · filed 2025-11-14 | |||
| 2023-12-31 | $4.45M 10-K · filed 2025-03-28 | |||
| 2023-09-30 | $1.05M 10-Q · filed 2024-11-14 | $2.14M derived: sum of 2 quarters · filed 2024-11-14 | $3.36M derived: sum of 3 quarters · filed 2024-11-14 | |
| 2023-06-30 | $1.09M 10-Q · filed 2024-11-14 | $2.31M derived: sum of 2 quarters · filed 2024-11-14 | ||
| 2023-03-31 | $1.21M 10-Q · filed 2024-11-14 | |||
| 2022-12-31 | $5.78M 10-K · filed 2024-02-29 | |||
| 2022-09-30 | $1.48M 10-Q · filed 2023-11-07 | $2.88M derived: sum of 2 quarters · filed 2023-11-07 | $4.39M derived: sum of 3 quarters · filed 2023-11-07 | |
| 2022-06-30 | $1.40M 10-Q · filed 2023-11-07 | $2.91M derived: sum of 2 quarters · filed 2023-11-07 | ||
| 2022-03-31 | $1.51M 10-Q · filed 2023-11-07 | |||
| 2021-12-31 | $5.66M 10-K · filed 2023-03-29 | |||
| 2021-09-30 | $1.74M 10-Q · filed 2022-11-08 | $3.48M derived: sum of 2 quarters · filed 2022-11-08 | $4.83M derived: sum of 3 quarters · filed 2022-11-08 | |
| 2021-06-30 | $1.75M 10-Q · filed 2022-11-08 | $3.09M derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-03-31 | $1.35M 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | $1.49M 10-K · filed 2022-03-15 | |||
| 2020-09-30 | $781.00K 10-Q · filed 2021-11-10 | $944.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.14M derived: sum of 3 quarters · filed 2021-11-10 | |
| 2020-06-30 | $163.00K 10-Q · filed 2021-11-10 | $357.00K derived: sum of 2 quarters · filed 2021-11-10 | ||
| 2020-03-31 | $194.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |